- About About
-
Medical
Medical
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
-
Advocacy
Advocacy
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
-
Policy
Policy
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America
- Join Join
-
-
New Memo from Congressional Research Service
The Congressional Research Service (CRS) released a memorandum analyzing the Justice Department’s Decision to rescind Obama-era guidance on federal cannabis policy including the Cole Memo, the Ogden Memos, the Wilkinson memo on cannabis on tribal lands and the FinCen guidance which created policies for financial institutions interacting with cannabis businesses. CRS is a non-partisan office in the Library of Congress that provides legislative advice and analysis to both parties in a neutral way.
The memo released by CRS highlights that the move by the Justice Department gives greater flexibility to individual federal prosecutors and decentralizes federal policy on cannabis enforcement decisions. The memo also indicates that without centralized federal guidance on cannabis, there is greater uncertainty as it could allow simultaneously for “continued restraint or more aggressive enforcement.”
Federal protections for medical cannabis patients through the CJS Medical Marijuana patients expire on Friday, January 19th without action by Congress.
Share